clinical trial · NCT05663411
A Study of SHR6508 in Secondary Hyperparathyroidism
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase2·unknown·n = 75
Secondary HyperparathyroidismSHR6508SHR6508Cinacalcet
brief summary
The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
started
Feb 24, 2023
primary completion
Oct 31, 2023
completion
Nov 30, 2023
last updated
Jun 18, 2023
official title
An Open-label, Randomized, Active-Controlled Dose Titration Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol